Literature DB >> 27639313

Lung adenocarcinomas: correlation of computed tomography and pathology findings.

J G Cohen1, E Reymond2, A Jankowski3, E Brambilla4, F Arbib5, S Lantuejoul6, G R Ferretti7.   

Abstract

Adenocarcinoma is the most common histologic type of lung cancer. Recent lung adenocarcinoma classifications from the International Association for the Study of Lung cancer, the American Thoracic Society and the European Respiratory Society (IASLC/ETS/ERS, 2011) and World Health Organization (WHO, 2015) define a wide range of adenocarcinoma types and subtypes featuring different prognosis and management. This spectrum of lesions translates into various CT presentations and features, which generally show good correlation with histopathology, stressing the key role of the radiologist in the diagnosis and management of those patients. This review aims at helping radiologists to understand the basics of the up-to-date adenocarcinoma pathological classifications, radio-pathological correlations and how to use them in the clinical setting, as well as other imaging-related correlations (radiogenomics, quantitative analysis, PET-CT).
Copyright © 2016. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Computed tomography; Lung adenocarcinoma; Pathology; Solitary pulmonary nodule; Subsolid nodules

Mesh:

Year:  2016        PMID: 27639313     DOI: 10.1016/j.diii.2016.06.021

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  10 in total

1.  Pure ground-glass nodules: are they really indolent?

Authors:  Julien G Cohen; Gilbert R Ferretti
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

2.  Are shape morphologies associated with survival? A potential shape-based biomarker predicting survival in lung cancer.

Authors:  Maliazurina Saad; Ik Hyun Lee; Tae-Sun Choi
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-16       Impact factor: 4.553

Review 3.  Challenges in the target volume definition of lung cancer radiotherapy.

Authors:  Susan Mercieca; José S A Belderbos; Marcel van Herk
Journal:  Transl Lung Cancer Res       Date:  2021-04

4.  Development and Validation of a Combined Model for Preoperative Prediction of Lymph Node Metastasis in Peripheral Lung Adenocarcinoma.

Authors:  Qi Li; Xiao-Qun He; Xiao Fan; Chao-Nan Zhu; Jun-Wei Lv; Tian-You Luo
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

5.  Differences in lung cancer characteristics and mortality rate between screened and non-screened cohorts.

Authors:  Fu-Zong Wu; Pei-Lun Kuo; Yi-Luan Huang; En-Kuei Tang; Chi-Shen Chen; Ming-Ting Wu; Yun-Pei Lin
Journal:  Sci Rep       Date:  2019-12-18       Impact factor: 4.379

6.  Pulmonary lymphoepithelioma-like carcinoma: A case report with emphasis on computed tomography findings.

Authors:  Lin Zhou; Xin-Yi Liu; Ya He; Lu-Ting Li; Shao-Jin Zhang
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

7.  N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.

Authors:  Jian Zheng; Zhuochen Zhao; Junhu Wan; Manman Guo; Yangxia Wang; Zhengwu Yang; Zhuofang Li; Liang Ming; Zhaobing Qin
Journal:  J Clin Lab Anal       Date:  2021-09-24       Impact factor: 2.352

8.  Differential diagnosis of localized pneumonic-type lung adenocarcinoma and pulmonary inflammatory lesion.

Authors:  Qi Li; Xiao Fan; Ji-Wen Huo; Tian-You Luo; Xing-Tao Huang; Jun-Wei Gong
Journal:  Insights Imaging       Date:  2022-03-22

9.  A lepidic adenocarcinoma mimicking an eosinophilic lung.

Authors:  L Senhaji; B Alami; M Serraj; M El Biaze; M C Benjelloun; B Amara
Journal:  Respir Med Case Rep       Date:  2022-08-04

10.  Computed Tomography Morphological Classification of Lung Adenocarcinoma and Its Correlation with Epidermal Growth Factor Receptor Mutation Status: A Report of 1075 Cases.

Authors:  Xiao-Qun He; Xing-Tao Huang; Qi Li; Xiao Fan; Tian-You Luo; Ji-Wen Huo
Journal:  Int J Gen Med       Date:  2021-07-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.